Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 64

1.

Role of serum P1NP measurement for monitoring treatment response in osteoporosis.

Samoszuk M, Leuther M, Hoyle N.

Biomark Med. 2008 Oct;2(5):495-508. doi: 10.2217/17520363.2.5.495.

PMID:
20477426
2.
3.

Physical activity and bone turnover markers: a cross-sectional and a longitudinal study.

Adami S, Gatti D, Viapiana O, Fiore CE, Nuti R, Luisetto G, Ponte M, Rossini M; BONTURNO Study Group.

Calcif Tissue Int. 2008 Dec;83(6):388-92. doi: 10.1007/s00223-008-9184-8. Epub 2008 Oct 24.

PMID:
18949504
4.

Between hyperfiltration and impairment: demystifying early renal functional changes in diabetic nephropathy.

Rosolowsky ET, Niewczas MA, Ficociello LH, Perkins BA, Warram JH, Krolewski AS.

Diabetes Res Clin Pract. 2008 Nov 13;82 Suppl 1:S46-53. doi: 10.1016/j.diabres.2008.09.018. Epub 2008 Oct 11. Review.

PMID:
18849087
5.

Genome-wide single-nucleotide polymorphism studies in rheumatology: hype or hope?

van der Helm-van Mil AH, Padyukov L, Toes RE, Klareskog L, Huizinga TW.

Arthritis Rheum. 2008 Sep;58(9):2591-7. doi: 10.1002/art.23751. No abstract available.

6.

New automated multiplex assay for bone turnover markers in osteoporosis.

Claudon A, Vergnaud P, Valverde C, Mayr A, Klause U, Garnero P.

Clin Chem. 2008 Sep;54(9):1554-63. doi: 10.1373/clinchem.2008.105866. Epub 2008 Aug 1.

7.

Comparison between immunoturbidimetry, size-exclusion chromatography, and LC-MS to quantify urinary albumin.

Shaikh A, Seegmiller JC, Borland TM, Burns BE, Ladwig PM, Singh RJ, Kumar R, Larson TS, Lieske JC.

Clin Chem. 2008 Sep;54(9):1504-10. doi: 10.1373/clinchem.2008.107508. Epub 2008 Jul 10.

8.

Disease-dependent mechanisms of albuminuria.

Comper WD, Hilliard LM, Nikolic-Paterson DJ, Russo LM.

Am J Physiol Renal Physiol. 2008 Dec;295(6):F1589-600. doi: 10.1152/ajprenal.00142.2008. Epub 2008 Jun 25. Review.

9.

High-density single nucleotide polymorphism genome-wide linkage scan for susceptibility genes for diabetic nephropathy in type 1 diabetes: discordant sibpair approach.

Rogus JJ, Poznik GD, Pezzolesi MG, Smiles AM, Dunn J, Walker W, Wanic K, Moczulski D, Canani L, Araki S, Makita Y, Warram JH, Krolewski AS.

Diabetes. 2008 Sep;57(9):2519-26. doi: 10.2337/db07-1086. Epub 2008 Jun 16.

10.

American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis.

Saag KG, Teng GG, Patkar NM, Anuntiyo J, Finney C, Curtis JR, Paulus HE, Mudano A, Pisu M, Elkins-Melton M, Outman R, Allison JJ, Suarez Almazor M, Bridges SL Jr, Chatham WW, Hochberg M, MacLean C, Mikuls T, Moreland LW, O'Dell J, Turkiewicz AM, Furst DE; American College of Rheumatology.

Arthritis Rheum. 2008 Jun 15;59(6):762-84. doi: 10.1002/art.23721. No abstract available.

11.

Urinary proteomics in diabetes and CKD.

Rossing K, Mischak H, Dakna M, Zürbig P, Novak J, Julian BA, Good DM, Coon JJ, Tarnow L, Rossing P; PREDICTIONS Network.

J Am Soc Nephrol. 2008 Jul;19(7):1283-90. doi: 10.1681/ASN.2007091025. Epub 2008 Apr 30.

12.

The cell biology of bone metabolism.

Datta HK, Ng WF, Walker JA, Tuck SP, Varanasi SS.

J Clin Pathol. 2008 May;61(5):577-87. doi: 10.1136/jcp.2007.048868. Review.

PMID:
18441154
13.

Biomarkers of bone health and osteoporosis risk.

Eastell R, Hannon RA.

Proc Nutr Soc. 2008 May;67(2):157-62. doi: 10.1017/S002966510800699X. Review.

PMID:
18412989
14.

Pharmacogenetics of hypersensitivity to abacavir: from PGx hypothesis to confirmation to clinical utility.

Hughes AR, Spreen WR, Mosteller M, Warren LL, Lai EH, Brothers CH, Cox C, Nelsen AJ, Hughes S, Thorborn DE, Stancil B, Hetherington SV, Burns DK, Roses AD.

Pharmacogenomics J. 2008 Dec;8(6):365-74. doi: 10.1038/tpj.2008.3. Epub 2008 Mar 11. Review.

PMID:
18332899
15.

Establishing a reference range for bone turnover markers in young, healthy women.

Glover SJ, Garnero P, Naylor K, Rogers A, Eastell R.

Bone. 2008 Apr;42(4):623-30. doi: 10.1016/j.bone.2007.12.218. Epub 2008 Jan 5.

PMID:
18289953
16.

MCP-1/CCL2: a new diagnostic marker and therapeutic target for progressive renal injury in diabetic nephropathy.

Tesch GH.

Am J Physiol Renal Physiol. 2008 Apr;294(4):F697-701. doi: 10.1152/ajprenal.00016.2008. Epub 2008 Feb 13. Review.

17.

HLA-B*5701 screening for hypersensitivity to abacavir.

Mallal S, Phillips E, Carosi G, Molina JM, Workman C, Tomazic J, Jägel-Guedes E, Rugina S, Kozyrev O, Cid JF, Hay P, Nolan D, Hughes S, Hughes A, Ryan S, Fitch N, Thorborn D, Benbow A; PREDICT-1 Study Team.

N Engl J Med. 2008 Feb 7;358(6):568-79. doi: 10.1056/NEJMoa0706135.

18.

Association of urinary inflammatory markers and renal decline in microalbuminuric type 1 diabetics.

Wolkow PP, Niewczas MA, Perkins B, Ficociello LH, Lipinski B, Warram JH, Krolewski AS.

J Am Soc Nephrol. 2008 Apr;19(4):789-97. doi: 10.1681/ASN.2007050556. Epub 2008 Feb 6.

19.

Value of the HLA-B*5701 allele to predict abacavir hypersensitivity in Spaniards.

Rodríguez-Nóvoa S, García-Gascó P, Blanco F, González-Pardo G, Castellares C, Moreno V, Jiménez-Nácher I, González-Lahoz J, Soriano V.

AIDS Res Hum Retroviruses. 2007 Nov;23(11):1374-6. doi: 10.1089/aid.2006.0244.

PMID:
18184080
20.

Systematic review: comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis.

MacLean C, Newberry S, Maglione M, McMahon M, Ranganath V, Suttorp M, Mojica W, Timmer M, Alexander A, McNamara M, Desai SB, Zhou A, Chen S, Carter J, Tringale C, Valentine D, Johnsen B, Grossman J.

Ann Intern Med. 2008 Feb 5;148(3):197-213. Epub 2007 Dec 17.

PMID:
18087050

Supplemental Content

Support Center